Elanco Animal Health Inc
NYSE:ELAN

Watchlist Manager
Elanco Animal Health Inc Logo
Elanco Animal Health Inc
NYSE:ELAN
Watchlist
Price: 12.88 USD -1.08% Market Closed
Market Cap: 6.4B USD

Elanco Animal Health Inc
Investor Relations

Elanco Animal Health Inc. emerged from the hallowed halls of Eli Lilly and Company, officially standing on its own in 2018, and immediately carving out its identity as a key player in animal health. The company, headquartered in Greenfield, Indiana, prides itself on working at the intersection of science and animal well-being, bringing innovative solutions to the market. Elanco's operations revolve around two primary business segments: Companion Animal and Farm Animal. In the Companion Animal segment, the focus is squarely on developing products that improve the health and extend the lives of pets, from flea and tick treatments to vaccines that safeguard them against disease. This segment taps into the growing humanization of pets, leveraging the emotional bond between owners and animals to drive demand for premium pet healthcare products.

On the other hand, Elanco's Farm Animal segment is deeply woven into the fabric of the agricultural ecosystem, serving the needs of livestock operations around the globe. This division offers a suite of products that enhance the health and productivity of cattle, swine, poultry, and aqua species, addressing concerns from disease prevention to growth efficiency. By providing antibiotics, vaccines, and other nutritional health additives, Elanco helps farmers meet the world's growing demand for protein while complying with the ever-stringent regulations on animal product safety and efficacy. The company's diversified portfolio and its global reach allow it to monetize the vast and varied animal health landscape effectively, positioning itself as a stalwart in the sector dedicated not just to animal care but to elevating the industry standards through innovation and responsible growth.

Show more
Loading

Earnings Calls

2022 Q4
May 16, 2023
Show Transcript
Previous
Next
Capcom Targets Growth with Strong Digital Sales and New Titles
2022 Q4
May 16, 2023

Capcom is poised for robust growth, leveraging its digital content business amid a booming global gaming market expected to grow from $203.4 billion in 2022 to $242.1 billion by 2027. For FY '23, Capcom projects consolidated net sales to rise by JPY 14.07 billion to JPY 140 billion, with operating income expected to reach JPY 56 billion and an operating margin of 40%. Key releases like Street Fighter 6 are anticipated to boost sales, contributing to a forecasted 11th consecutive year of operating income growth. The company aims for 45 million unit sales, emphasizing new games and digital sales to solidify its market position.

Management

Mr. Jeffrey N. Simmons
President, CEO & Director
No Bio Available
Mr. Todd S. Young J.D.
Executive VP & CFO
No Bio Available
Dr. Ramiro Martin Cabral
Executive Vice President of Elanco International
No Bio Available
Dr. Ellen de Brabander Ph.D.
Executive Vice President of Research, Development & Regulatory Affairs
No Bio Available
Mr. Timothy J. Bettington
Executive Vice President of Corporate Strategy & Market Development
No Bio Available
Mr. James M. Meer
Senior VP & Chief Accounting Officer
No Bio Available
Mr. Chris Keeley
Senior VP & Chief Information Officer
No Bio Available
Mr. David S. Kinard
Executive Vice President of Human Resources, Corporate Communications & Administration
No Bio Available
Ms. Katy Grissom
Head of Investor Relations
No Bio Available
Ms. Shiv O'Neill
Executive Vice President, General Counsel & Corporate Secretary
No Bio Available

Contacts

Address
INDIANA
Greenfield
2500 Innovation Way N
Contacts
+18773526261.0
www.elanco.com